Table 1.
Baseline characteristics of the study population receiving intervention of a dietary supplementation of selenium and coenzyme Q10 combined during 4 years
| Active | Placebo | p value | |
|---|---|---|---|
| N | 157 | 151 | |
| Age years mean (SD) | 76 (3) | 77 (3) | 0.34 |
| Males/females n | 79/78 | 72/79 | |
| History | |||
| Diabetes n (%) | 32 (20.4) | 29 (19.2) | 0.80 |
| Smoking n (%) | 11 (7.0) | 13 (8.6) | 0.60 |
| Hypertension n (%) | 114 (72.6) | 109 (72.2) | 0.93 |
| IHD n (%) | 28 (17.8) | 35 (23.2) | 0.25 |
| NYHA class I n (%) | 93 (59.2) | 76 (50.3) | 0.12 |
| NYHA class II n (%) | 39 (24.8) | 47 (31.1) | 0.22 |
| NYHA class III n (%) | 24 (15.3) | 26 (17.9) | 0.65 |
| NYHA class IV n (%) | 0 | 0 | |
| BMI mean (SD) | 27.4 (4.07) | 27.0 (4.18) | 0.44 |
| Hb < 120 g/L n (%) | 15 (9.6) | 16 (10.6) | 0.76 |
| Medications | |||
| ACEI/ARB n (%) | 30 (19.1) | 40 (26.5) | 0.12 |
| Beta blockers n (%) | 56 (35.7) | 53 (35.1) | 0.92 |
| Diuretics n (%) | 49 (31.2) | 61 (40.4) | 0.09 |
| Statins n (%) | 35 (22.3) | 32 (21.2) | 0.81 |
| Examinations | |||
| EF < 40% n (%) | 12 (7.6) | 11 (7.3) | 0.90 |
| Atrial fibrillation n (%) | 9 (5.7) | 12 (7.9) | 0.44 |
| s-Selenium µg/L, mean (SD) | 66.6 (15.9) | 67.4 (17.2) | 0.56 |
ACEI ACE-inhibitors, ARB angiotension receptor blockers, EF ejection fraction, IHD ischemic heart disease, NYHA New York Heart Association functional class, SD standard deviation